Yes. Tirzepatide is a peptide made from 39 amino acids. More precisely, it is a modified synthetic peptide designed to activate both the GIP and GLP-1 receptors.
That answer clears up two common sources of confusion. “Peptide” describes the molecule’s amino-acid structure; “dual GIP/GLP-1 receptor agonist” describes what the molecule is designed to do. Tirzepatide can be both at the same time.
Why tirzepatide is classified as a peptide
Peptides are chains of amino acids joined by peptide bonds. Tirzepatide has a 39-amino-acid backbone based on the sequence of glucose-dependent insulinotropic polypeptide, better known as GIP. Researchers then modified that backbone to produce the molecule’s two-receptor activity and longer duration.
The FDA’s current Zepbound prescribing information describes tirzepatide as a GIP-receptor and GLP-1-receptor agonist and provides its chemical description. A peer-reviewed review of tirzepatide’s structure likewise identifies it as a 39-amino-acid synthetic peptide.
Being synthetic does not make it “not a peptide.” Synthetic refers to how the molecule is produced; peptide refers to the type of molecule it is.
What the 39-amino-acid structure means
The phrase “tirzepatide amino acid sequence” often suggests a simple unmodified string of residues. Tirzepatide is more accurately understood as an engineered peptide structure. Its amino-acid backbone includes substitutions, and a fatty-diacid-containing side chain is attached through a linker.
That side chain promotes binding to albumin. According to the FDA label, albumin binding contributes to an elimination half-life of approximately five days. The modification is therefore part of the molecule’s pharmacologic design, not merely a manufacturing detail.
| Structural feature | What it tells us |
|---|---|
| 39-amino-acid backbone | Tirzepatide is a peptide |
| Sequence based on GIP | GIP receptor activity is central to its design |
| Activity at GIP and GLP-1 receptors | It is a dual receptor agonist |
| Fatty-diacid-containing side chain | Albumin binding helps prolong exposure |
This is also why a product name or a shorthand sequence alone is not enough to establish identity. Analytical confirmation of a peptide may require methods such as mass spectrometry and HPLC; our guide to HPLC versus mass spectrometry explains what each test can and cannot show.
Is tirzepatide a GLP-1?
Calling tirzepatide “a GLP-1” is understandable shorthand, but it leaves out half of the mechanism. Tirzepatide activates the GLP-1 receptor and the GIP receptor. The more precise description is dual GIP/GLP-1 receptor agonist.
GLP-1 and GIP are incretin hormones involved in post-meal signaling. Tirzepatide is a single molecule designed to engage both receptor systems; it is not a mixture of two separate peptides.
Tirzepatide, semaglutide and retatrutide are not interchangeable
These molecules are frequently discussed together, but the receptor design is different in each case.
| Molecule | Receptor activity | Current regulatory context in the United States |
|---|---|---|
| Semaglutide | GLP-1 | Active ingredient in FDA-approved prescription products |
| Tirzepatide | GIP + GLP-1 | Active ingredient in FDA-approved prescription products |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational; not FDA approved |
The extra receptor label does not by itself prove that one molecule is better for a particular person. Molecules differ in structure, exposure, studied dose, trial population and safety profile.
There are direct clinical data for some comparisons. In the 2025 SURMOUNT-5 trial, tirzepatide produced a greater mean reduction in body weight than semaglutide at 72 weeks among adults with obesity but without diabetes. The peer-reviewed SURMOUNT-5 report should be read with its population, doses and adverse-event data rather than as a universal ranking of the two molecules.
For a focused receptor comparison, see semaglutide versus tirzepatide. For the investigational three-receptor program, see our updated retatrutide Phase 3 guide.
Is tirzepatide the same as Mounjaro or Zepbound?
Tirzepatide is the active ingredient. Mounjaro and Zepbound are brand names for finished FDA-approved prescription medicines containing tirzepatide. A research reference material bearing the molecule’s name is not the same thing as either approved product and should not be presented as a substitute.
Certiva’s tirzepatide product page describes a lyophilized reference material for laboratory research. Researchers evaluating such material should review the batch-specific certificate and distinguish identity testing from purity testing; our guide to reading a peptide COA explains that process.
So the concise answer remains: tirzepatide is a 39-amino-acid, structurally modified synthetic peptide, and its defining pharmacologic feature is dual activity at the GIP and GLP-1 receptors.
Sources and further reading
- FDA: Zepbound prescribing information
- Tirzepatide structure and 39-amino-acid design
- SURMOUNT-5: tirzepatide compared with semaglutide
- Retatrutide triple-agonist Phase 2 trial
This article is educational and is not medical advice. Certiva materials are for laboratory research use only and are not medicines.
Frequently asked questions
Is tirzepatide a peptide?
Yes. Tirzepatide is a synthetic peptide containing 39 amino acids. Its structure is based on the GIP sequence and is modified to activate both GIP and GLP-1 receptors and to extend its duration of action.
Is tirzepatide a GLP-1 peptide?
Tirzepatide activates the GLP-1 receptor, but it is more accurately described as a dual GIP and GLP-1 receptor agonist because it targets both receptor systems.
How many amino acids are in tirzepatide?
Tirzepatide contains 39 amino acids. It also has structural modifications, including a fatty-diacid-containing side chain that contributes to albumin binding and a longer half-life.
How is tirzepatide different from semaglutide?
Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors, so it is called a dual agonist.
Is tirzepatide the same as Mounjaro or Zepbound?
Tirzepatide is the active ingredient in the FDA-approved prescription products Mounjaro and Zepbound. The brand names refer to finished medicines, while tirzepatide is the name of the active molecule.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More peptide basics guides · Have a question? Start an inquiry →